Secondary prevention of cervical cancer part 2: Initial management of abnormal cervical cancer screening test

Clinical Obstetrics and Gynecology

Volumn 57, Issue 2, 2014, Pages 292-301

  Guido, Richard ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

cervical cancer; colposcopy; management; screening

Indexed keywords

ABNORMAL LABORATORY RESULT; ARTICLE; CANCER GRADING; CANCER SCREENING; COLPOSCOPY; CYTODIAGNOSIS; GENOTYPE; HEALTH CARE DELIVERY; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRACTICE GUIDELINE; PREGNANT WOMAN; SCREENING TEST; SECONDARY PREVENTION; SPONTANEOUS ABORTION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DIAGNOSIS; FEMALE; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; STANDARDS; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PRACTICE GUIDELINES AS TOPIC; SECONDARY PREVENTION; UTERINE CERVICAL NEOPLASMS;

EID: 84900387405     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0000000000000033     Document Type: Article

References (20)

1. Solomon D, Breen N, McNeel T. Cervical cancer screening rates in the United States and the potential impact of implementation of screening guidelines. CA Cancer J Clin. 2007;57:105-111.
2. Wright TC, Cox JT, Massad LS, et al. 2001 Consensus guidelines for the management of women with cervical intraepithelial neoplasia. J Low Genit Tract Dis. 2003;7:154-167.
3. Wright TC, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the managementofwom-en with abnormal cervical screening tests. J Low Genit Tract Dis. 2007;11:201-222.
4. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17:S1-S27.
5. Katki HA, Schiffman M, Castle PE, et al. Five-year risk of CIN 3+ to guide the management of women aged21to24years.JLow Genit Tract Dis. 2013;17:S64-S68.
6. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colpo-scopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis. 2012;16:175-204.
7. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119.
8. Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis. 2012;16:205-242.
9. Siebers AG, Klinkhamer PJJM, Vedder JEM, et al. Causes and relevance of unsatisfactory and satisfactory but limited smears of liquid-based compared with conventional cervical cytology. Arch Pathol Lab Med. 2012;136:76-83.
10. Elumir-Tanner L, Doraty M. Management of Papanicolaou test results that lack endocervical cells. CMAJ. 2011;183:563-568.
11. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12: 663-672
12. ASCUS-LSIL Triage Study Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188:1383-1392.
13. ASCUS-LSIL Triage Study Group.Arandomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003;188:1393-1400.
14. Sherman ME, Castle PE, Solomon D. Cervical cytology of atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): characteristics and histologic outcomes. Cancer. 2006;108:298-305.
15. Moscicki A-B. HPV infections in adolescents. Dis Markers. 2007;23:229-234.
16. Moscicki A-B, Ma Y, Wibbelsman C, et al. Rate of and risks for regression of cervical intraepithe-lial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010;116:1373-1380.
17. Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis. 2013;17:S28-S35.
18. Moscicki A-B, Schiffman M, Burchell A, et al. Updating the natural history of human papillo-mavirus and anogenital cancers. Vaccine. 2012;30 (suppl 5):F24-F33.
19. Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Infect Dis Soc Am Clin Infect Dis. 1994;18: 421; 98.
20. Kish MA. Guide to development of practice guidelines. Clin Infect Dis. 2001;32:851-854.